CVS Caremark®

|  |
| --- |
| Reference number(s) |
| 3011-A |

# Specialty Guideline Management Visudyne

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
| --- | --- |
| Visudyne | verteporfin |

## Indications

### FDA-approved Indications1

Visudyne for injection is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis.

### Compendial Uses2,3

* Classic subfoveal choroidal neovascularization due to chronic central serous chorioretinopathy
* Choroidal hemangioma

All other indications are considered experimental/investigational and not medically necessary.

## Coverage Criteria

### Choroidal Neovascularization1,2

Authorization of 6 months may be granted for treatment of predominantly classic subfoveal choroidal neovascularization (CNV) when both of the following criteria are met:

* Member has predominantly classic subfoveal choroidal neovascularization due to ONE of the following:
  + Age-related macular degeneration
  + Pathologic myopia
  + Presumed ocular histoplasmosis
  + Chronic central serous chorioretinopathy (also includes retinal pigment epithelial leakage without evident CNV)
* The treatment spot size is less than or equal to 6.4 mm in diameter.

### Choroidal Hemangioma3

Authorization of 6 months may be granted for treatment of choroidal hemangioma.

## Continuation of Therapy

Authorization of 12 months may be granted for continued treatment of an indication listed in coverage criteria section for members who have demonstrated a positive clinical response to therapy.

## References

1. Visudyne [package insert]. Charleston, SC: Alcami Carolinas Corporation; February 2023.
2. van Rijssen, T.J., van Dijk, E.H.C., Yzer, S., Ohno-Matsui, K., Keunen, J.E.E., Schlingemann, R.O., Sivaprasad, S., Querques, G., Downes, S.M., Fauser, S., Hoyng, C.B., Piccolino, F.C., Chhablani, J.K., Lai, T.Y.Y., Lotery, A.J., Larsen, M., Holz, F.G., Freund, K.B., Yannuzzi, L.A., Boon, C.J.F., Central serous chorioretinopathy: Towards an evidence-based treatment guideline, Progress in Retinal and Eye Research (2019), doi: https://doi.org/10.1016/j.preteyeres.2019.07.003.
3. Tsipursky MS, Golchet PR, Jampol LM. Photogynamic therapy of choroidal hemangioma in sturge-weber syndrome, with a review of treatments for diffuse and circumscribed choroidal hemangiomas. Surv Ophthalmol. 2011; 56 (1): 68-85.